From Tumour to Bloodstream: Advancing PD-L1 Testing With Liquid Biopsies in Non-Small Cell Lung Cancer
{{output}}
Immune checkpoint inhibitors (ICIs) have revolutionised the treatment landscape of non-small cell lung cancer (NSCLC) without actionable genomic alterations by opening new possibilities for treatment. However, the predictive value of Programmed Death-Ligand 1 ... ...
